Real-world efficacy and safety of re-treatment with [177Lu] Lu-DOTA-TATE in patients with neuroendocrine tumors (NETs)

#4192

Introduction: The established efficacy and safety of [177Lu]-DOTA-TATE in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and bronchial NETs (G1, G2) have paved the way for exploration into re-treatment ([177Lu] RR-PRRT) safety and efficacy, an area with limited available data.

Aim(s): This study aims to evaluate the safety and efficacy of [177Lu] RR-PRRT in patients with progressive GEP-NETs or lung NETs following standard-dose PRRT.

Materials and methods: A retrospective multicenter study conducted from July 2018 to October 2023 involved 31 patients. Tumor characteristics, treatment history, outcomes, and adverse events (AEs) were comprehensively analysed.

Conference:

Presenting Author: Martinez Lago N

Authors: Martinez Lago N, Hernando Cubero J, Calatayud A, Velazquez F, Anido U,

Keywords: Re-treatment, PRRT, neuroendocrine, 177Lu,